文献速递银屑病与炎症性皮肤病

古塞奇尤单抗对比阿达木单抗和安慰剂治疗特定部位银屑病的疗效:2项随机临床试验的二次分析

Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials.
PubMed 文献 · JAMA Dermatol · 2018-01-01

基于VOYAGE 1和VOYAGE 2两项双盲随机试验的二次分析,评估古塞奇尤单抗对头皮、掌跖和甲银屑病的疗效。第24周时,古塞奇尤单抗在头皮和掌跖部位的疗效优于阿达木单抗,而甲银屑病改善程度两者无差异。

要点

  • 第16周古塞奇尤单抗头皮ss-IGA 0/1达81.8%,优于安慰剂12.4%(P<.001)。
  • 第24周古塞奇尤单抗掌跖hf-PGA 0/1达80.4%,优于阿达木单抗60.3%(P<.001)。
  • 第24周甲f-PGA 0/1古塞奇尤单抗60.0% vs 阿达木单抗64.3%,无显著差异(P=.11)。

核心结论

  • 与阿达木单抗相比,古塞奇尤单抗与头皮及掌跖银屑病的显著改善相关。
  • 甲银屑病的改善程度在两种治疗之间无差异。
  • 作者认为这些结果可能有助于皮肤科医生为难治部位银屑病患者做出治疗决策。

研究设计与样本

  • VOYAGE 1和VOYAGE 2为双盲、安慰剂和阿达木单抗对照的古塞奇尤单抗研究。
  • 两项研究分别在全球101家和115家中心开展,时间为2014年11月3日至2016年5月19日。
  • 患者为中重度斑块状银屑病,银屑病面积和严重程度指数评分≥12、研究者全球评估评分≥3且银屑病累及体表面积≥10%。
  • 本分析为事后数据分析,于2017年2月10日至2017年11月15日进行。
  • 共1829例随机患者,平均(SD)年龄43.6(12.4)岁,1300例(71.1%)男性,1498例(81.9%)白人。

主要发现

  • 1576例(86.2%)有头皮银屑病,501例(27.4%)有掌跖银屑病,1049例(57.4%)有甲银屑病。
  • 基线时分别有1512例(82.7%)、461例(25.2%)和928例(50.7%)的ss-IGA、hf-PGA和f-PGA评分≥2并纳入分析。
  • 第16周ss-IGA 0/1:古塞奇尤单抗组560例(81.8%)vs 安慰剂组43例(12.4%)。
  • 第24周ss-IGA 0/1:古塞奇尤单抗组582例(85.0%)vs 阿达木单抗组329例(68.5%),均P<.001;ss-IGA 0:古塞奇尤单抗组479例(69.9%)vs 阿达木单抗组270例(56.3%),均P<.001。
  • 第16周hf-PGA 0/1:古塞奇尤单抗组154例(75.5%)vs 安慰剂组15例(14.2%);第24周古塞奇尤单抗组164例(80.4%)vs 阿达木单抗组91例(60.3%);hf-PGA 0:古塞奇尤单抗组153例(75.0%)vs 阿达木单抗组76例(50.3%),均P<.001。

关键数值与推荐

  • 古塞奇尤单抗给药方案:100 mg,第0周和第4周给药,之后每8周一次。
  • 安慰剂组从第16周开始接受古塞奇尤单抗100 mg。
  • 阿达木单抗给药方案:第0周80 mg,第1周40 mg,之后每2周一次。

临床怎么用

  • 作者认为这些结果可能有助于皮肤科医生为难治部位银屑病患者做出治疗决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Psoriasis of the scalp, palms and/or soles, and nails is challenging to treat. OBJECTIVE: To evaluate the effect of guselkumab on psoriasis in specific body regions. DESIGN, SETTING, AND PARTICIPANTS: VOYAGE 1 and VOYAGE 2 were, double-blind, placebo- and adalimumab-controlled studies of guselkumab conducted at 101 and 115 global sites, respectively, from November 3, 2014, to May 19, 2016. Patients had moderate to severe plaque psoriasis (Psoriasis Area and Severity Index score ≥12, Investigator's Global Assessment [IGA] score ≥3, and ≥10% body surface area with psoriasis). This post hoc data analysis was performed from February 10 through November 15, 2017. EXPOSURES: Patients were randomized to guselkumab, 100 mg (weeks 0 and 4, then every 8 weeks); placebo followed by guselkumab, 100 mg, starting at week 16; or adalimumab (80 mg [week 0] and 40 mg [week 1, then every 2 weeks]). MAIN OUTCOMES AND MEASURES: Efficacy was assessed through week 24. End points included numbers of patients achieving scores of 0 or 1 (clear or near clear) or 0 (clear) on the scalp-specific IGA (ss-IGA), Physician's Global Assessment of the hands and/or feet (hf-PGA), and fingernail PGA (f-PGA) and percentage of improvement in target Nail Psoriasis Severity Index score. RESULTS: Of 1829 randomized patients (mean [SD] age, 43.6 [12.4] years; 1300 [71.1%] male, 1498 [81.9%] white), 1576 (86.2%) had psoriasis of the scalp; 501 (27.4%), palms and/or soles; and 1049 (57.4%), fingernails. At baseline, 1512 (82.7%), 461 (25.2%), and 928 (50.7%) patients had a score of 2 or higher on the ss-IGA, hf-PGA, and f-PGA, respectively, and were included in the analysis. Guselkumab was superior to placebo based on the proportion of patients achieving an ss-IGA score of 0 or 1 (560 [81.8%] vs 43 [12.4%]) at week 16 and to adalimumab (582 [85.0%] vs 329 [68.5%]) at week 24 (both P < .001); 479 (69.9%) in the guselkumab group vs 270 (56.3%) in the adalimumab group achieved an ss-IGA score of 0 (all P < .001). An hf-PGA score of 0 or 1 was achieved by 154 patients (75.5%) in the guselkumab group vs 15 (14.2%) in the placebo group at week 16 and 164 (80.4%) in the guselkumab group vs 91 (60.3%) in the adalimumab group at week 24; 153 (75.0%) in the guselkumab group vs 76 (50.3%) in the adalimumab group achieved an hf-PGA score of 0 (all P < .001). An f-PGA score of 0 or 1 was achieved by 196 patients (46.7%) in the guselkumab group vs 32 (15.2%) in the placebo group at week 16 (P < .001) and 252 (60.0%) in the guselkumab group vs 191 (64.3%) in the adalimumab group at week 24 (P = .11); 115 (27.4%) in the guselkumab group vs 83 (27.9%) in the adalimumab group achieved an f-PGA score of 0 (P = .63). CONCLUSIONS AND RELEVANCE: Compared with adalimumab, guselkumab was associated with significant improvement in psoriasis on the scalp and palms and/or soles; magnitude of improvement in fingernails did not differ between treatments. These results may help dermatologists make treatment decisions for patients with psoriasis in difficult-to-treat body regions. TRIAL REGISTRATION: ClinicalTrials.gov Identifiers: NCT02207231 and NCT02207244.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Foley P, Gordon K, Griffiths CEM, et al. Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials. JAMA Dermatol. 2018. PMID: 29799960. doi:10.1001/jamadermatol.2018.0793

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。